Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation

Tina Marinelli, Li Yan A. Wee, Emily Rowe, Rakchha Chhetri, Oisin Friel, Geoffrey Higgins, Peter Bardy, Deepak Singhal, Alyssa Pradhan, Lucy Crawford, Devendra K. Hiwase

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Common respiratory viral infections (CRVIs) frequently complicate hematopoietic stem cell transplantation (HSCT). We conducted a retrospective, single-center, observational cohort study to determine the incidence of CRVI in patients who received an allogeneic (allo) or autologous (auto) HSCT at the Royal Adelaide Hospital between 2009 and 2017. The median follow-up was 8.9 and 4.5 years for auto- and allo-HSCT recipients, respectively. There were 149 CRVI episodes in 74 patients, with rhinovirus being the most commonly isolated virus (n = 81, 47%). The majority of CRVIs (113/149, 75.8%) occurred more than 100 days post-HSCT and 67% were diagnosed in the outpatient setting. There was evidence of lower respiratory tract infection (LRTI) in 45.6% (68/149) of CRVIs. On multivariate logistic regression analysis, coviral infections and cytomegalovirus viremia were independent risk factors for progression of CRVI to LRTI. Ten (6.7%) CRVI episodes resulted in admission to intensive care for ventilatory support and 8 (5.4%) patients died within 30 days of CRVI diagnosis. In our study, 10.4% of HSCT recipients experienced a CRVI post-transplant, primarily causing late morbidity and potentially mortality. Prevention with strict infection control practices, vaccination, and patient education is essential.

Original languageEnglish
Pages (from-to)782-788
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number4
Publication statusPublished or Issued - Apr 2020


  • Respiratory virus
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this